Article Text

Download PDFPDF
PWE-075 Endoscopic radiofrequency ablation for high-grade dysplasia or intramucosal cancer in Barrett's oesophagus – results from the first 100 patients enrolled in the UK HALO radiofrequency ablation registry
  1. J M Dunn1,
  2. S Thorpe1,
  3. G M Fullarton2,
  4. H Smart3,
  5. I Penman4,
  6. P Patel5,
  7. R Willert6,
  8. M R Novelli7,
  9. M B Banks8,
  10. L B Lovat8
  1. 1National Medical Laser Centre, University College London, London, UK
  2. 2Department of Surgery, Glasgow Royal Infirmary, Glasgow, Scotland, UK
  3. 3Department of Gastroenterology, Royal Liverpool University Hospital, Liverpool, UK
  4. 4Department of Gastroenterology, Western General and Royal Infirmary, Edinburgh, Scotland, UK
  5. 5Department of Gastroenterology, Southampton General Hospital, Southampton, UK
  6. 6Department of Gastroenterology, Central Manchester University Hospital, Manchester, UK
  7. 7Department of Pathology, University College London, UK
  8. 8Gastroenterology, University College London Hospital, London, UK


Introduction The incidences of Barrett's oesophagus (BE) and associated oesophageal adenocarcinoma are increasing rapidly in the UK. Radiofrequency ablation (RFA) with a circumferential balloon based device (CA) and endoscope-mounted focal ablation device (FA) are promising modalities for treating dysplasia arising in BE.

Aim To determine the safety and efficacy of RFA for treating dysplastic BE in a UK patient cohort.

Study Design Multicentre UK registry (seven teaching and private hospitals; treatment period from April 2007 to November 2009). Patients with histological evidence of dysplasia or intramucosal cancer (IMC) arising in BE confirmed by two specialist GI pathologists were included in the study. A prior endoscopic mucosal resection (EMR) was permitted, provided that residual dysplasia remained in the BE region for ablation. RFA was performed every 3 months with follow-up biopsy upon achieving either complete endoscopic eradication of BE or after four consecutive ablations. The primary endpoint was complete response for high-grade dysplasia (CR-HGD), dysplasia (CR-D) and intestinal metaplasia (CR-IM), defined as no biopsy showing each respective finding.

Results A total of 106 patients (79% male, median age 69 years, interquartile range (IQR) 50–83 years) have been treated so far. Accrual rates now exceed 15 patients per quarter. 83 had HGD, 22 IMC, 1 LGD. Median length of BE was 6 cm (IQR 1–15 cm). 54% had prior EMR, 25% had previous photodynamic therapy (PDT) or argon plasma coagulation (APC).

42 patients have completed treatment with at least 1 follow-up biopsy session (median follow-up 4 months, IQR 2–24). Median number of treatments is 1 CA (IQR 0–3) and 1 FA (IQR 0–3). CR-HGD was achieved in 90% of patients, CR-D in 79% and CR-IM in 33%. There were eight new strictures, three mucosal injuries during RFA (1.5%) and one perforation (patient previously treated with PDT) (0.5%).

Conclusion Reversal of IM is currently poor, but many of these patients have had multiple previous ablative therapies and may represent a particularly difficult group to treat. Despite this, radiofrequency ablation safely achieved a CR- HGD in 90% of patients treated within a UK multicentre registry. These data are similar to other registries.

Statistics from

Request Permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.